Organon & Co.
OGN · NYSE
Bulios Fair Price
$9.21
32.6% downside
Current Price
$13.67
According to Bulios Fair Price, OGN is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Organon & Co. (OGN) is an international pharmaceutical company specializing in the research, development, and production of medicinal products and medical use products. The company focuses on a wide range of therapeutic areas, including women's health, neurology, cardiology, endocrinology, and others. Organon & Co. provides medicines and treatment options for patients with various health needs, contributes to the development of new drugs and innovative treatment procedures. The company emphasizes the high quality, safety, and effectiveness of its products and is dedicated to improving the health and quality of life of patients. Organon & Co. collaborates with medical professionals, research institutions, and healthcare organizations worldwide. Shares of Organon & Co. represent an intriguing investment opportunity for those who believe in the prospects of the pharmaceutical industry and its contributions to human health.
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Joseph T. Morrissey Jr.
Employees
10,000
Headquarters
Jersey City
Upcoming events
Earnings
Upcoming earnings report